Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

fool.com - Thomas Niel - Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait.
Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait.
The Motley Fool –

Bristol Myers Squibb (BMY -1.54%) has one of the highest dividend yields among major pharmaceutical stocks. At current prices, its shares have a forward yield of around 4.2%. However, consider the yield not as the sole reason to buy, but as an…

euronews.com - Angela Barnes - Why pharma giant Roche is putting German investments on hold
Why pharma giant Roche is putting German investments on hold
Euronews.com –

Swiss pharmaceutical giant Roche said on Monday it would put expansion in Germany on hold, dealing a blow to Berlin as a government-backed investment summit got underway. 'We have put all future investment decisions in Germany on hold for the time…

hoodline.com - Edith Carmichael - Apothecary Pharma Recalls Tirzepatide Vials Nationwide
Apothecary Pharma Recalls Tirzepatide Vials Nationwide
Hoodline –

A Cary, North Carolina pharmacy is recalling 22 vials of compounded tirzepatide after federal regulators said the company cannot assure the products were made sterile, and the recall has already shipped nationwide. Apothecary Pharma LLC initiated…

techcrunch.com - Julie Bort - OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business
OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business
TechCrunch –

OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week Low - Should You Sell?
Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week Low - Should You Sell?
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday. The stock traded as low as $22.24 and last traded at $23.57, with a volume of 9,188 shares. The stock had previously closed at $23.33.

marketbeat.com - Avalyn Pharma Inc.'s Lock-Up Period Set To End on October 27th (NASDAQ:AVLN)
Avalyn Pharma Inc.'s Lock-Up Period Set To End on October 27th (NASDAQ:AVLN)
MarketBeat –

Avalyn Pharma's (NASDAQ:AVLN - Get Free Report) lock-up period will expire on Tuesday, October 27th. Avalyn Pharma had issued 16,666,667 shares in its public offering on April 30th. The total size of the offering was $300,000,006 based on an…

seekingalpha.com - Albert Anthony - STAG Industrial: Buy Reaffirmed Ahead Of Q3 Earnings, Amid Tailwind From E-Commerce
STAG Industrial: Buy Reaffirmed Ahead Of Q3 Earnings, Amid Tailwind From E-Commerce
Seeking Alpha –

Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…

foxbusiness.com - Bradford Betz - GLP-1 injections recalled nationwide over sterility concerns
GLP-1 injections recalled nationwide over sterility concerns
Fox Business –

Apothecary Pharma is recalling 23 vials of injectable drugs distributed nationwide because their sterility cannot be assured, according to the Food and Drug Administration. The voluntary recall includes 22 vials of compounded tirzepatide, a GLP-1…

nypost.com - Allie Yang - GLP-1 injections recalled nationwide - what to know about the affected products
GLP-1 injections recalled nationwide - what to know about the affected products
New York Post –

An unexpected shot of bad news. A popular weight-loss shot has been recalled across the country by the FDA due to potential contamination. The US-based compounding pharmacy that issued the initial recall back in September had already been on the…

fool.com - Ben Gran - Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.
The Motley Fool –

Kevin Warsh's Federal Open Market Committee (FOMC) has its next meeting on Oct. 28 to decide on a course of action for interest rates. It looks as if they aren't coming down anytime soon. According to the CME Group 's proprietary FedWatch tool…

thehindu.com -  The Hindu Bureau - Pinarayi Vijayan questions SMA drug distribution; SAT Hospital says only CDSCO-approved drugs used
Pinarayi Vijayan questions SMA drug distribution; SAT Hospital says only CDSCO-approved drugs used
The Hindu –

Even as the Leader of the Opposition, Pinarayi Vijayan, cried foul that “experimental drugs” meant for “clinical trials” were being distributed to SMA patients, SAT Hospital authorities have clarified that only drugs…

tuzarapost.substack.com - Joe Tuzara, M.D. @TuzaraPost - Big Pharma's Body Count: Prescription Drugs Now the Leading Cause of Death, Surpassing Heart Disease and Cancer
Big Pharma's Body Count: Prescription Drugs Now the Leading Cause of Death, Surpassing Heart Disease and Cancer
Tuzara Post Newsletter –

A landmark re-analysis of drug mortality data has delivered a verdict the medical establishment has spent decades avoiding: pharmaceuticals have overtaken heart disease and cancer to become the single leading cause of death. Our prescription drugs…

axios.com - Alex Fitzpatrick - New mission will test making cancer drugs in space
New mission will test making cancer drugs in space
Axios –

Orbital pharma and re-entry startup Varda Space Industries launched a new mission Tuesday to test microgravity's effects on an innovative cancer treatment. Why it matters: Developing medicine in space, away from the pesky influence of Earth's…

news-medical.net - Chronic Hand Eczema (CHE) is affecting NHS healthcare professionals and can impact patient care, report finds
Chronic Hand Eczema (CHE) is affecting NHS healthcare professionals and can impact patient care, report finds
News-Medical –

LEO Pharma and the British Skin Foundation (BSF) today launched a new report exploring the impact of Chronic Hand Eczema (CHE) on NHS healthcare professionals (HCPs) and the wider healthcare workforce. CHE is a fluctuating inflammatory skin…

fool.com - Brendan Coffey - AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool –

Choosing between established dividend payers and high-growth innovators is a classic investor dilemma. This comparison pits AbbVie (ABBV +2.26%) against Vertex Pharmaceuticals (VRTX +2.53%) to determine which company offers the best balance of risk…

Receive a Daily briefing on Pharma Industry News

Get Started